Remgro (REM) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
20 Jan, 2026Executive summary
Headline earnings fell 20% to ZAR 5.65 billion, with headline EPS down 18.8%, mainly due to non-recurring items and a challenging macroeconomic environment.
Ordinary dividend increased 10% to 264c, with a 15% rise in the final dividend and INAV per share up 1%.
Strategic focus on portfolio optimization, integration of unlisted assets, and unlocking value through divestments and new growth opportunities.
Significant progress in deleveraging, divestments, and new shareholder partnerships.
Local reforms and easing inflation provided positive momentum for medium-term portfolio growth.
Financial highlights
Headline earnings decreased by 20% year-over-year to ZAR 5.65 billion, with muted operational performance from key investments.
HEPS declined 18.8% to 1,018c; closing share price R136.09, down 7.5% year-over-year.
Dividend per share increased 10% year-over-year, with a final dividend up 15%.
INAV per share rose 1%, supported by share repurchases and strong listed asset performance; INAV discount widened to 45.8%.
Net cash at the center increased by ZAR 3.2 billion, despite a ZAR 2.2 billion decrease in cash due to preference share redemption.
Outlook and guidance
Management expects continued improvement in the second half, with green shoots in key investments and a focus on operational turnarounds.
Anticipates further growth in OUTsurance, Rainbow, and RCL Foods, with ongoing efforts to improve Mediclinic and Heineken performance.
CIVH's growth is contingent on regulatory approval of the Vodacom transaction, with plans to accelerate fiber rollout if approved.
Improving local operating context and reform momentum expected to support medium-term portfolio growth.
Focus remains on executing strategic priorities, including ESG leadership and enhanced disclosure.
Latest events from Remgro
- HEPS expected to rise 36%–41% year-over-year for the six months ended 31 December 2025.REM
H1 2026 TU13 Mar 2026 - All resolutions passed as shareholders engaged on strategy, incentives, and global risks.REM
AGM 202412 Jan 2026 - Portfolio is 63% private, with growth led by Mediclinic and CIVH, and focus on ESG and performance.REM
CMD 202520 Dec 2025 - Headline earnings up 38.7%, INAV per share up 10.3%, and dividend up 20%.REM
H1 20251 Dec 2025 - Maziv's ZAR 38.75bn deal advances with regulatory support, CapEx, and BEE commitments.REM
Investor Update13 Nov 2025 - Headline earnings up 38.6%, ordinary dividend up 30.3%, and balance sheet fully de-geared.REM
H2 202516 Oct 2025